On the one hand, irbesartan suppressed the Hippo/YAP1/c-Jun axis and further directly enhanced the responsiveness of tumour cells to chemotherapy in KPC genetically engineered mouse model; on the other hand, irbesartan also reduced desmoplasia and solid stress in PDAC tumors and further increased the therapeutic drug diffusion. Here, JUN is linked to neoplasm.